P688: ASC2ESCALATE: A US PHASE 2, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND-LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)

• Ehab Atallah,
• Michael Mauro,
• Koji Sasaki,
• Moshe Yair Levy,
• Paul Koller,
• Islam Sadek,
• Daisy Yang,
• Julie Ruckel-Kumar,
• Mahmudul Khan,
• Jorge Cortes

Affiliations

Ehab Atallah

1 Medical College of Wisconsin, Milwaukee, United States

Michael Mauro

2 Memorial Sloan Kettering Cancer Center, New York, United States

Koji Sasaki

3 The University of Texas MD Anderson Cancer Center, Houston, United States

Moshe Yair Levy

4 Baylor Scott & White Health, Dallas, United States

Paul Koller

5 City of Hope National Medical Center, Duarte, United States

Islam Sadek

6 Novartis Pharmaceuticals Corporation, East Hanover, United States

Daisy Yang

6 Novartis Pharmaceuticals Corporation, East Hanover, United States

Julie Ruckel-Kumar

6 Novartis Pharmaceuticals Corporation, East Hanover, United States

Mahmudul Khan

6 Novartis Pharmaceuticals Corporation, East Hanover, United States

Jorge Cortes

7 Georgia Cancer Center, Augusta, United States